Nat. Rev. Urol. doi: /nrurol

Slides:

Advertisements

Similar presentations

Tyrosine kinase signalling (review) TGF signalling Notch signalling.

Advertisements

Trends in prostate cancer and its management in the South West Region, Hampshire and the Isle of Wight Christine Harling Julia Verne (SWPHO) Roy Maxwell.

South West Public Health Observatory The changing casemix of prostate cancer patients and prostatectomies in the South West Sean McPhail.

Prostate cancer and socio-economic deprivation When PCTs are ranked according to their income score using the Indices of Multiple Deprivation (IMD)* there.

Philipp Dahm, Ari D. Silverstein, Alon Z

Nat. Rev. Urol. doi: /nrurol

Oncology for Family Medicine Residents:

#96 Roles Of Urodynamics In the Assessment of Post Radical

Accountable Care Organizations and Prostate Cancer Care

Figure 1 Number of somatic mutation rates across The Cancer Genome Atlas (TCGA) projects Figure 1 | Number of somatic mutation rates across The Cancer.

Nat. Rev. Urol. doi: /nrurol

Figure 3 Life expectancy at birth in all countries included

Figure 1 Male infertility and assisted reproduction globally

Nat. Rev. Urol. doi: /nrurol

Figure 2 Recruitment of experts to the Delphi study

Nat. Rev. Urol. doi: /nrurol

Figure 5 Schematic illustration of different clinical trial designs

Mastectomy and Reconstruction In Asian Breast Cancer Patients

Nat. Rev. Urol. doi: /nrurol

Figure 3 Semantic model of the active surveillance (AS) timeline

Nat. Rev. Urol. doi: /nrurol

Figure 2 Representative images from a right radical

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 3 Proportion of patients for whom NEDA

Figure 1 Key elements of the proposed modified Delphi study

Nat. Rev. Urol. doi: /nrurol

Figure 1 The burden of chronic kidney disease (CKD)

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 2 Schema for the phase II Randomized Observation versus

External Beam Radiotherapy as Curative Treatment of Prostate Cancer

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 The development process of the Asian

Figure 3 Drug cycling with collateral sensitivity

Figure 1 Differences in bladder cancer between genders

Figure 13 Proposed management of bladder cancer with variant histology

Nat. Rev. Urol. doi: /nrurol

Figure 3 Treatment algorithm for adult infertile men with varicoceles

Figure 3 Algorithm for the determination of the clinical

Nat. Rev. Urol. doi: /nrurol

Figure 6 Image sequence demonstrating coronal cuts on MRI

Figure 2 White matter hyperintensities

Nat. Rev. Urol. doi: /nrurol

Figure 3 Differences in renal cell carcinoma (RCC) between genders

Figure 3 Template for standard pelvic lymphadenectomy

Nat. Rev. Urol. doi: /nrurol

Figure 2 Age-specific prevalence of common comorbidities

the SNP profile using 26 prostate cancer GWAS risk SNPs

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 1 A hierarchy of steps need to be

Figure 2 The evolution of brachytherapy for prostate cancer

Figure 1 Timing of the effects of deep brain stimulation

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 4 The grey zone between active

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 3 Determination of the primary site

Figure 4 Algorithm for when to determine PTEN

Number of patients treated at clinics that followed up fewer than 10 patients (2013–2016) or 20 patients (2012) and proportion of patients followed up.

Cases of and deaths from prostate cancer, with associated age-standardized incidence and mortality (per men), among Canadian men aged 45 years.

Presentation transcript:

Nat. Rev. Urol. doi:10.1038/nrurol.2016.52 Figure 2 Pie charts indicating primary treatment patterns in the USA stratified by age Figure 2 | Pie charts indicating primary treatment patterns in the USA stratified by age. The increased ageing population means that clinicians are more often faced with the need to tailor prostate cancer care to elderly patients. Younger patients (<64 years) are most often treated with surgery, with over 50% of men undergoing radical prostatectomy. As patients age, the likelihood of undergoing prostatectomy decreases, with only 33% of men aged 65-74 years and 4% of men aged > 75 years receiving surgical treatment. As populations live longer and prostate cancer is diagnosed in a higher proportion of elderly men, a lack of consideration of life expectancy and comorbidities means that the disproportionate number of elderly patients who do not receive treatment is likely to increase. Kalra, S. et al. (2016) The implications of aging and life expectancy in prostate cancer treatment Nat. Rev. Urol. doi:10.1038/nrurol.2016.52